These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37107120)

  • 1. Pharmacokinetics and Pharmacodynamics of Florfenicol in Plasma and Synovial Fluid of Pigs at a Dose of 30 mg/kg
    Somogyi Z; Mag P; Simon R; Kerek Á; Szabó P; Albert E; Biksi I; Jerzsele Á
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against
    Somogyi Z; Mag P; Kovács D; Kerek Á; Szabó P; Makrai L; Jerzsele Á
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PK-PD Integration Modeling and Cutoff Value of Florfenicol against
    Lei Z; Liu Q; Yang S; Yang B; Khaliq H; Li K; Ahmed S; Sajid A; Zhang B; Chen P; Qiu Y; Cao J; He Q
    Front Pharmacol; 2018; 9():2. PubMed ID: 29387013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial activity of combined aditoprim and sulfamethoxazole against Escherichia coli from swine and a dose regimen based on pharmacokinetic-pharmacodynamic modeling.
    Wang F; Luo W; Pan Y; Qu W; Xie S; Huang L; Wang Y
    J Vet Pharmacol Ther; 2022 Jan; 45(1):133-145. PubMed ID: 34435681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine
    Luo W; Wang D; Qin H; Chen D; Pan Y; Qu W; Huang L; Xie S
    J Vet Sci; 2021 Nov; 22(6):e41. PubMed ID: 34854264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistant cutoff values and optimal scheme establishments for florfenicol against Escherichia coli with PK-PD modeling analysis in pigs.
    Lei Z; Liu Q; Khaliq H; Cao J; He Q
    J Vet Pharmacol Ther; 2019 May; 42(3):324-335. PubMed ID: 30801741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs.
    Huang L; Zhang H; Li M; Ahmad I; Wang Y; Yuan Z
    BMC Vet Res; 2018 Oct; 14(1):319. PubMed ID: 30355326
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Xiao X; Lan W; Zhao Y; Li R; Liu Y; Liu J; Wang Z
    Front Microbiol; 2020; 11():616685. PubMed ID: 33505384
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic integration and modelling of florfenicol in calves.
    Sidhu P; Rassouli A; Illambas J; Potter T; Pelligand L; Rycroft A; Lees P
    J Vet Pharmacol Ther; 2014 Jun; 37(3):231-42. PubMed ID: 24341543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing tylosin dosage for co-infection of
    Lee EB; Abbas MA; Park J; Tassew DD; Park SC
    Front Pharmacol; 2023; 14():1258403. PubMed ID: 37808183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
    Dorey L; Pelligand L; Cheng Z; Lees P
    PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate.
    Aliabadi FS; Lees P
    J Vet Pharmacol Ther; 2002 Jun; 25(3):161-74. PubMed ID: 12081611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic integration for optimal dosage of cefquinome against Streptococcus equi subsp. equi in foals.
    Lee DH; Birhanu BT; Lee EB; Lee SJ; Boby N; Park YS; Park SC
    Vet Res; 2020 Oct; 51(1):131. PubMed ID: 33059768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for
    Zhou YF; Peng HM; Bu MX; Liu YH; Sun J; Liao XP
    Front Pharmacol; 2017; 8():684. PubMed ID: 29033841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.
    Zhao Y; Guo LL; Fang B; Liu B
    PLoS One; 2018; 13(12):e0209177. PubMed ID: 30596709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synovial fluid pharmacokinetics of tulathromycin, gamithromycin and florfenicol after a single subcutaneous dose in cattle.
    Jones ML; Washburn KE; Fajt VR; Rice S; Coetzee JF
    BMC Vet Res; 2015 Feb; 11():26. PubMed ID: 25886555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PK-PD Analysis of Marbofloxacin against
    Lei Z; Liu Q; Yang B; Khaliq H; Cao J; He Q
    Front Pharmacol; 2017; 8():856. PubMed ID: 29209222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PK/PD integration of florfenicol alone and in combination with doxycycline against
    Zhang H; Huang Y; Yu J; Liu X; Ding H
    Front Vet Sci; 2022; 9():975673. PubMed ID: 36157174
    [No Abstract]   [Full Text] [Related]  

  • 19. Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets.
    Zhou YF; Bu MX; Liu P; Sun J; Liu YH; Liao XP
    BMC Vet Res; 2020 Mar; 16(1):81. PubMed ID: 32138735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE; Golden JA; Kelley MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.